Medical Oncology
The 51-year-old man discussed in this case presents with an 8-year history of a mole on the upper back that displayed no suspicious symptoms until it began bleeding in 2004. Several months later, he underwent a biopsy and removal of the mole, which proved to be a superficial spreading melanoma of 5.5-mm Breslow depth. Subsequent wide local incision with intraoperative lymphatic mapping and sentinel lymph node (SNL) biopsy showed no residual melanoma; the lymph node was negative. No lymphadenopathy is found on physical examination, and the patient's incision is well-healed. His performance status is excellent. Family history indicates his mother had gastric cancer, and the patient reports a history of tobacco smoke exposure; both are likely noncontributory to his melanoma. The patient has been recommended to undergo interferon therapy and presents for a second opinion.
Superficial spreading melanoma is the most common type of melanoma, making up approximately 65% of melanoma cases. The typical features of asymmetry and irregular border, color variation, and diameter are widely used to promote public awareness of skin cancer and high-risk lesions. This melanoma appears to be solitary; the physical examination does not reveal other suspicious lesions or dysplastic nevi. The patient is reported to have a medium tan complexion, and freckles are not reported. No exposure to industrial chemicals associated with melanoma (eg, coal tar, arsenic) or immune-suppressing medications is reported. His history of sun exposure is not, however, reported, and it is likely that his melanoma has resulted from excess sun exposure. Based on results of a recent meta-analysis, intermittent sun exposure along with history of sunburn may be a particularly potent risk factor for cutaneous melanoma. 1 Melanoma surgery, staging, and adjuvant treatment have recently undergone reassessments based on an emerging body of literature on outcomes and on consideration by expert panels. In the area of surgery, a consensus process was undertaken to assess the indications for SNL biopsy in different clinical situations for patients with early-stage melanomas. 2 Based on an extensive literature review, an expert panel determined that SNL biopsy was appropriate for patients with melanomas greater than 1 mm in thickness, as well as for those less than 1 mm but with ulceration or higher levels of invasion of dermal tissues. With the 5.5-mm tumor of the present patient, SNL biopsy was certainly indicated, and thus surgical procedures were appropriate. No satellite nodes were found on wide local excision, and, in addition to the absence of nodal metastasis, this indicates localized disease.
Staging for melanoma has evolved over the past decade. 3 Important earlier staging systems drew on the tumor-staging concepts of Clark, which depended on the degree of invasion of the dermal tissues, and of Breslow, which depended on the thickness of the melanoma itself. The American Joint Committee on Cancer (AJCC) staging criteria published in 1997 included both Clark's and Breslow's concepts in the staging of the primary tumor and adopted a tumornode-metastasis (TNM) model for clinical staging. Work toward a new AJCC system began in 1999, after a critical analysis of the 1997 system was published. 4 The new AJCC staging system for melanoma (which was adopted in 2002) relies on 2 different variables for staging of the primary tumor: Breslow depth and ulceration. Nodal classification is based on the numbers of positive lymph nodes and whether micrometastases or macrometastases are detected. The patient in question was found to have a 5.5-mm tumor, and SNL biopsy revealed no nodal metastasis. The depth of his tumor places him in the T4 classification under the new system and, based on the clinical TNM classification, in stage II. Under the 1997 system, this tumor would have also been classified as a T4 tumor, but the TNM classification of the 1997 system would have indicated stage III.
Adjuvant treatment of stage II tumor was considered in the same consensus process as SNL biopsy. 2 The expert panel involved considered the adjuvant use of high-dose interferon-α2b (IFN) as indicated for node-negative patients only when the primary tumor was deeper than 4.0 mm, as is the case with this patient. The adjuvant use of high-dose IFN in such high-risk patients is based on a series of important clinical trials published from 1996 to 2001. Among these is the Eastern Cooperative Oncology Group trial that randomized 287 patients with stage IIB or III melanoma (older system classification) to either IFN or observation. Relapse-free survival (1.7 years vs 0.9 years) and overall survival (3.8 years vs 2.8 years) favored the IFN group. 5 A subsequent trial also found an improvement in relapse-free, though not overall, survival (many patients in the observation group crossed over to interferon-α salvage therapy after experiencing recurrences in this trial, which may have affected overall survival). 6 Finally, a trial with 880 patients of IFN versus a ganglioside vaccine found significantly better relapse-free survival and overall survival in the IFN group. 7 Recent meta-analyses, however, show that IFN treatment is by no means an optimal adjuvant therapy for melanoma. A 2003 review, for instance, acknowledging the positive survival results above, pointed out that subsequent trials did not maintain the effect on overall survival and that the survival curves were somewhat immature. Trials of low-dose and intermediate-dose interferon also had inconsistent results and had no impact on overall survival. 8 A subsequent meta-analysis that included updated survival curves on the studies of high-dose interferon discussed above also found that relapse-free but not overall survival was improved in high-dose interferon. 9 This meta-analysis found that the factors that were associated with shorter survival in these trials were recurrent disease, ulceration, and age older than 49 years.
Other regimens for adjuvant treatment of high-risk melanoma have also undergone recent large clinical trials. A regimen that included low-dose IFN and lowdose interleukin-2 failed to find a survival differential from the control group. 10 A trial of extended (2-year) administration of low-dose IFN also failed to find any improvement of relapse-free or overall survival. 11 No survival benefit for Bacillus Calmette-Guerin (BCG) or BCG plus dacarbazine was seen in a large trial in patients with stages I to III melanoma. 12 Several vaccines for melanoma are in earlier stages of clinical trials, but overall survival data are not available from these trials, and high-dose IFN remains the bestrecognized Food and Drug Administration-approved adjuvant therapy for melanoma in a stage II patient. 13 That the present patient does not have recurrent disease and that his age is not much older than 49 years are encouraging for his possible response to IFN treatment.
IFN is a therapy that modifies immune response to melanoma, one of the few cancers that can be treated through immune mechanisms. As such, it should be of great interest to the many cancer patients interested in alternative medicine means of treating cancer through immune stimulation, with the idea that such a "natural" means of treatment will be easier to tolerate. In reality, this year-long regimen has proved as difficult to manage and tolerate as any cytotoxic chemotherapy, although it has a somewhat different set of toxicities. Kirkwood et al divided these toxicities into acute and chronic manifestations. 14 Well known to IFN patients is the flulike syndrome that most patients experience. These constitutional symptoms include fever, chills, myalgia, headache, nausea, and vomiting; they may be experienced to some degree by 94% of patients, while 48% of patients in the EST 1684 trial experienced grade 3 or 4 symptoms. 4 Skin reactions include alopecia and localized reactions at the injection site. Laboratory abnormalities are also common; 92% of patients experienced neutropenia in the EST 1684 trial, while 63% experienced some degree of liver toxicity. 4 Serum triglycerides may increase but return to normal after discontinuing therapy.
Chronic toxicities include a fatigue that tends to worsen as treatment goes on. 7 Approximately 25% of patients may experience severe fatigue. 4 Depression is a common mood disorder among patients under IFN treatment, although only a very small percentage experience suicidal ideas. Other neurological symptoms associated with IFN treatment may include shortterm memory or attention problems, psychomotor slowing, or poor coordination; rarely, these will persist for years after termination of therapy. Anorexia has been reported among 30% to 80% of patients in different IFN studies. Some of the factors that can contribute to it are nausea, impaired gastrointestinal motility, constipation, bloating, and food aversions or taste alterations. 7 Weight loss can result if anorexia is severe. Thyroid problems (hypothyroidism or hyperthyroidism) can also occur in up to 20% of patients.
Laboratory monitoring, especially white blood cell counts and liver function tests, needs to be done regularly. Standard hematological and blood chemistry tests, including thyroid-stimulating hormone levels, need to be done at the initiation of treatment and periodically during treatment. Granulocyte counts less than 500 cells/m 3 or alanine aminotransferase or aspartate aminotransferase levels higher than 5 times normal call for withholding treatment until the test results return to grade 1 or normal levels. With appropriate dose modification, most patients can undergo a year of treatment.
